SLx-4090
DrugSLx-4090
NCT Number: NCT00871936
The purpose of this study is to determine whether SLx-4090 in combination with metformin therapy will reduce HbA1c in patients with Type 2 Diabetes more effectively than metformin therapy alone.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Phase 2
Anaheim, California, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
SLx-4090
matching tablets
Time frame: 12 weeks
Time frame: 12 weeks
Response Pharmaceuticals
Industry
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of SLx-4090 in Combination With Metformin in Subjects With Type 2 Diabetes
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05986097
Diabetes Mellitus, Diabetes Mellitus, Type 2
Ann Arbor, Michigan, United States
View Trial DetailsNCT04256486
Diabetes Mellitus, Diabetes Mellitus, Type 2
Springdale, Arkansas, United States
View Trial DetailsNCT05601583
Cognition Disorders, Cognitive Dysfunction
New York, United States
View Trial DetailsNCT06649773
Diabetes Mellitus, Diabetes Mellitus, Type 2
Beijing, Beijing Municipality, China
View Trial Details